As shown in Table 2, after adjusting for age, DM, HTN, hyperlipidemia, CKD, Aspirin, NSAIDs, Statins, metformin, beta-blockers, and renin-angiotensin system (angiotensin-converting enzyme inhibitor, ACEI/angiotensin receptor blocker, ARB) drugs, trastuzumab treatment is associated with increased risk of HF, with an estimated hazard ratio (HR) of 1.193 (95% confidence interval [CI] 1.054–1.351, P = 0.0052). Here, ACE is linked to hyperlipidemia.